gandotinib
Small moleculeexperimental
Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 inhibitor, with additional minor inhibition of STAT3. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01134120)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1- Mol. weight
- 469.95 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGandotinib ↗
- ChEMBLCHEMBL2107823 ↗
Also known as
- gandotinib
- gandotinib
- gandotinib
- ly2784544
- ly2784544
- ly-2784544
- ly-2784544
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01520220 | Phase 1 | Jun 11, 2012 | Eli Lilly |
| NCT01594723 | Phase 2 | May 1, 2012 | Eli Lilly |
| NCT01134120 | Phase 1 | Apr 1, 2010 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2010 |
1 organizations
Page 1 / 1